Europe
Boys with good motor skills are better problem-solvers than their less skilful peers, a new study from Finland shows. In contrast to previous studies, the researchers found no association between aerobic fitness or overweight and obesity with cognitive function in boys.
Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD) (“C4XD”), a pioneering drug discovery company.
Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD)(“C4XD”), a pioneering drug discovery company.
Shares of Clovis Oncology fell more than 4 percent Friday after additional details surrounding GlaxoSmithKline’s $5.1 billion acquisition of Waltham, Mass.-based Tesaro Inc. was brought to life in a filing with the U.S. Securities and Exchange Commission.
Fidelta Ltd is pleased to announce that it has signed an integrated drug discovery agreement with Galapagos based on Fidelta’s macrocyclic platform.
Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients
Axovant Sciences, announced that it has licensed exclusive worldwide rights for the development and commercialization of two novel gene therapy programs to address GM1 gangliosidosis and GM2 gangliosidosis from the University of Massachusetts (UMass) Medical School.
NOXXON Pharma N.V., announced its decision to suspend trading on Friday, December 14, 2018.
VAXIMM AG, announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma.
The Lead Discovery Center GmbH (LDC) and the University of Duisburg-Essen (UDE) have received EUR 905,000 in funding from the state of North Rhine-Westphalia as part of its lead market competition, LifeSciences.NRW.
PRESS RELEASES